🍌 $BRUN (Boost Run) · 8-K filed Oct 06, 08:00 ET Inks $525.6M Five-Year GPU Cloud Agreement with Cohere Filed at $14.50 → Now $16.12 (+11.2%) Full breakdown 👇 🟢 Score 8/10 Source: Wiseek (link in bio)

🍌 We peeled $LW (Lamb Weston Holdings)'s 8-K · Oct 06, 08:02 ET Lamb Weston Beats Q1 Guidance and Raises Full-Year FY2027 Outlook Filed at $43.91 → Now $49.95 (+13.8%) Watch the breakdown 👇 🟢 Score 8/10 Source: Wiseek (link in bio)

$WBD — The public life of WBD is over. Skydance has completed its acquisition, taking Warner Bros. Discovery private in a ~$78 billion deal. Shareholders received $31.01666668 in cash per share, a figure that includes ticking consideration accrued since September 30. Trading in common stock halted, and the company is officially withdrawn from Nasdaq. This 8-K marks the terminal event for Warner Bros. Discovery as a public entity. We peeled this filing for the critical details. Effective immediately, CEO David Zaslav and CFO Gunnar Wiedenfels, along with all 13 incumbent directors and six named officers, have departed. A new board and officers, appointed by Merger Sub, are now in place. We also noted $7.94 million in transaction bonuses paid to three named executive officers. More significantly, the board ratified 396,804 RSU grants and 120,000 share issuances that occurred *after* the 2005 Non-Employee Director Incentive Plan had expired. That's a detail most won't catch. This definitive end for WBD concludes a saga that shaped its valuation for months. Shareholders received slightly above the last trading price of $30.95 at alert. The market moves on info. We peel it. Source & full breakdown: Wiseek (link in bio)

$UBER — just signaled its next growth vector: corporate catering. We've peeled the news: they're acquiring EzCater for $2.3 billion. This isn't just another bolt-on; it's a direct grab for higher-margin enterprise business. EzCater brings over $2.5 billion in annual gross bookings and a network of 140,000 restaurants directly into Uber Eats. The average order in this segment blows past $400, a significant jump from typical consumer deliveries. This deal radically expands Uber Eats' total addressable market. It follows closely on the heels of their $14.8 billion bid for Delivery Hero in July. These combined moves signal an aggressive, strategic pivot from Uber – consolidating food delivery dominance and now targeting the high-value enterprise segment. Previously, we saw the company prioritize $3.0 billion in share repurchases per its Q1 10-Q; now, capital is clearly earmarked for significant M&A to drive new growth. Watch for regulatory approvals in the coming months. The integration of EzCater's robust corporate network into Uber Eats will be key. This isn't just about market share; it's about shifting the revenue mix towards larger, more predictable orders. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$BLFS — is officially gone. This 8-K confirms the BioLife Solutions acquisition by Repligen has closed, completing the $1.5 billion deal. Each BioLife share converted into 0.1442 Repligen shares plus $11.25 in cash. Trading in BLFS halted at $39, and the stock will be delisted from Nasdaq, with deregistration to follow. Shareholders overwhelmingly approved the merger, with 40.9 million votes in favor and just 83,451 against. This filing marks the terminal event for BioLife Solutions equity holders, concluding a transaction we've been tracking since its announcement in July. The company ceases to exist as an independent public entity. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)

$PSKY — The $110 billion Warner Bros. Discovery merger is officially closed for PSKY. This 8-K confirms a complete capital overhaul, issuing 3.9 billion new Class B shares at $12.00. We've been tracking this. This isn't minor; we're also looking at $41.4 billion in new secured debt and another $8.5 billion in term loan facilities. For a company that recently sat around an $11 billion market cap, this fundamentally transforms the balance sheet and risk profile. The 3.9 billion PIPE shares represent substantial dilution, adding roughly 350% to the existing share count. This drastically alters per-share metrics. Beyond the financials, the entity rebrands to Skydance Corporation, relocates its listing to the NYSE under SKYD, and appoints a new President. This is more than just a merger; it's a new company with a profoundly different equity base. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$T — Leveraging external capital for network expansion. That's the core of T's new fiber joint venture with GIP and CPP Investments. This deal drastically expands AT&T's fiber footprint, accelerating deployment without fully consolidating the capital costs on its balance sheet. We flagged T's strategic push into fiber with the recent multi-year, multi-billion dollar Corning supply agreement. This JV, reported when shares were $24.25, further reinforces that commitment. It’s a smart move following the prior ~$23 billion EchoStar spectrum acquisition, solidifying their position in advanced connectivity and fixed wireless. The structure is key: grow the network faster while alleviating the funding burden, a clear positive for free cash flow. It allows for significant infrastructure build-out with shared investment. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$TOWN — TowneBank is aggressively expanding its North Carolina footprint. We just peeled news of their agreement to acquire Blueharbor Bank for approximately $154 million. This deal immediately boosts their presence in a key growth market within the Southeast. This isn't an isolated event. It follows TowneBank's strong Q2, where revenue more than doubled to $444.27 million. That surge was driven by a significant $198.55 million gain from the sale of its Resort Property Management business. The message is clear: streamline operations and deploy capital for targeted banking expansion. This acquisition solidifies their strategic direction and M&A appetite. Traders should monitor the upcoming regulatory and shareholder approvals. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$AVBP — ArriVent's lead drug firmonertinib failed its crucial Phase 3 FURVENT trial, missing the primary endpoint of progression-free survival. This isn't just a setback; it's a thesis-altering event for AVBP, whose valuation has been heavily reliant on this very asset. The trial's primary endpoint for first-line EGFR exon 20 insertion mutant NSCLC was not statistically significant. The 240mg dose showed a median PFS of 11.0 months versus 9.5 months for chemotherapy, with a Hazard Ratio of 0.75 and a p-value of 0.0654. We flagged this trial as central to the company's future, and its failure creates immediate and severe uncertainty regarding its development path forward. This filing hits a clinical-stage company where firmonertinib was the core value driver, despite prior FDA Breakthrough Therapy Designation and approval for *other* EGFR mutations in China. The company's Q2 report showed a $93.2M H1 net loss, and while cash runway was noted as 12+ months, the primary asset has just taken a major blow. Headlines are late. Filings aren't. Source & full breakdown: Wiseek (link in bio)

🍌 $PTC · news · Oct 05, 03:00 ET Schneider Electric to Acquire PTC for $205/Share in $22.6B All-Cash Deal Reported at $144.03 → Now $192.87 (+33.9%) Banancial breakdown 👇 🟢 Score 9/10 Source: Wiseek (link in bio)

$OPCH — Option Care Health is being acquired for $32.05 per share, valuing the company at $5.8 billion. This is a definitive agreement, confirming the advanced talks we flagged yesterday. The cash offer represents a significant premium to its last close of $28.16. CD&R will take majority ownership, with McKesson holding a minority stake. The company will go private, removing the overhang of CID therapy headwinds that pressured Q2 2026 gross margins and overall results. Shareholders will receive cash, ending public market exposure to these operational challenges. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)

$REGN — Regeneron just secured a $1.0 billion upfront payment and up to $7.0 billion in future milestones from Sanofi. This 8-K formalizes the expanded 20-year antibody alliance, adding four long-acting immunology antibodies to their pipeline. We peeled this filing. The $1.0 billion upfront is a significant cash injection, but for a $74.8 billion market cap, the real long-term leverage is in those $7.0 billion in milestones. Crucially, the deal also resolves the long-standing Dupixent commercialization lawsuit, removing a clear overhang for REGN. The expected $22 million IPR&D charge is immaterial. This filing confirms prior news, solidifying the financial terms and clearing legal uncertainty. We caught this. It's a clear bullish signal. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$BBIO — BridgeBio just secured Priority Review for its oral infigratinib in pediatric achondroplasia, setting a PDUFA date of February 4, 2027. This isn't just another drug; it's the first oral therapy candidate for the condition and slated to be a first-in-class approval. We flagged this as a major step forward for BBIO. The NDA is backed by strong Phase 3 PROPEL 3 data: a +2.10 cm/yr annualized height velocity improvement (p<0.0001). Crucially, it showed the first statistically significant gains in body proportionality and arm span in a randomized trial. This Priority Review shortens the FDA's clock to six months, pushing a decision roughly four months from now. BBIO plans a U.S. launch immediately upon approval, with an EMA submission targeted for Q4 2026. This move further solidifies BridgeBio's late-stage pipeline narrative, following closely on the heels of the BBP-418 FORTIFY trial success just yesterday. This accelerated pathway for infigratinib adds significant value to BBIO's portfolio. The market moves fast on these types of approvals. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)

$BDX — $19 billion. That's the real number. BDX is committing to a massive U.S. manufacturing investment, not the $3 billion President Trump initially flagged. This move secures crucial tariff relief for Becton Dickinson, countering earlier threats of new medical device tariffs by year-end. We caught this shift from the initial, understated news to the full scale of the deal. The agreement includes $3 billion specifically for expanding U.S. manufacturing, with over $1 billion heading to Nebraska. BDX will boost domestic supply of medical consumables by an additional five billion units annually, pushing total U.S. production to roughly 80%. All U.S. needles will now be made domestically using American steel. This isn't just about expansion; it’s a strategic alignment to onshore production under administration pressure, locking in protection from future trade levies. While the financial impact isn't yet quantified, this is a clear bullish signal for BDX, securing its position against significant tariff headwinds. Watch for details on final tariff policy scope and milestone achievements. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$CEG — Constellation Energy just locked in a massive 20-year Power Purchase Agreement with Google, injecting significant growth into its data-center pipeline. This isn't small potatoes: we're talking about adding 890 MW of nuclear capacity through uprates at 11 PJM units, backed by a $4.3 billion investment. A separate 15-year deal tacks on 2,700 MW of supply. This latest move builds directly on recent Amazon and Toyota agreements, solidifying CEG's strategy of leveraging existing assets for expansion. Uprates are key here; they offer faster, lower-risk capacity additions compared to new builds, maximizing efficiency. Given the company's Q2 beat and raised full-year EPS guidance to $11.50-$12.50, this deal sets the stage for further strong performance. The focus now shifts to execution timing and PJM capacity accreditation – those factors will determine the ultimate return profile of this substantial investment. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$RPM — Record Q1 results and a *raised* full-year growth outlook. Yet RPM trades near its 52-week low of $96. Sales jumped 4.8% to $2.216B, with diluted EPS up 13.6% to $2.01. Adjusted EBITDA also hit a record $405.5M, climbing 4.5%. Management upgraded full-year guidance to mid-single-digit sales and adjusted EBITDA growth, a bump from prior 3-7% and 5-10% ranges. Strong Performance Coatings and Consumer segments drove this, while Construction Products saw a 9.7% adjusted EBITDA decline. This momentum builds on the Volteco acquisition in September and the $700M buyback authorized in July. For Q2, RPM projects low- to mid-single digit sales and adjusted EBITDA growth. An Investor Day on November 9th could offer more upside. Given record profitability and an upgraded outlook, RPM is ripe for a re-rating from current levels. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)

$HPK — We flagged HPK's Q1 loss and debt covenant worries. This 8-K shows a decisive recapitalization. Indonesian state entities are injecting $450M into HPK via Series A 6.0% Perpetual Convertible Preferred Stock. The conversion price is set at $9.50 – a strong premium to the $8.08 market price we saw at alert. We peeled the details: the dividend rates escalate to 10% after year five. The new investors secure up to two board nomination rights, along with a two-year standstill and staggered transfer lockups. This capital infusion, combined with the recently announced $800M reserve-based credit facility, directly addresses the previously disclosed financial distress. Proceeds will primarily repay existing credit lines and fund working capital. The deal is subject to HSR approval, a fairness opinion for PT Tunas Harapan Perkasa, and other closing conditions, with an outside date of December 31, 2026. This comprehensive financial overhaul shifts the narrative for HPK. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)

$HUM — Minority shareholders in HUM are being forced out. Ambea, holding over 90% of the shares, is initiating a squeeze-out to acquire all remaining equity. We caught this news: Humana has formally applied for delisting. This move signals the definitive end of HUM's public trading. Remaining shareholders will be compelled to sell their shares at the squeeze-out price. An extraordinary general meeting is set for October 30 to elect a new board, cementing Ambea's full control. The delisting application confirms the final step in this takeover. Humana will no longer trade publicly. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$PCVX — The convertible notes portion of Vaxcyte's $1.15B capital raise is now formalized. This $500M offering, detailed in today's filing, matures in 2032. It converts to common stock at a premium to the $73.82 reference price, with settlement at the company's election in cash, shares, or a combination. This follows yesterday's positive Phase 3 VAX-31 data and the concurrent equity offering we flagged. Vaxcyte also disclosed $2.3 billion in cash as of September 30, 2026. This substantial raise aims to fund the VAX-31 commercial launch and manufacturing scale-up. While it shores up their balance sheet, these convertible notes introduce potential future dilution to existing shareholders upon conversion. The equity and debt offerings are independent; neither is contingent on the other. We peeled into the specifics of this capital structure. This isn't just about the overall sum; the terms of conversion and settlement will dictate future impact. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)

$BBNX — just cratered 37% to $18.95. This massive drop follows disclosure of medical device safety issues and a securities fraud class action filing. The stock now trades just above its recent September offering price of $17.25, erasing substantial gains. This sudden reversal comes after a period of strong momentum for Beta Bionics. We saw Q2 revenue grow 38% to $32 million, FDA clearance for their Mint patch pump, and a significant $172.5 million capital raise. The narrative shifted fast. The safety disclosure and accompanying litigation introduce critical regulatory and legal risks. Management will face significant distraction, potentially derailing the crucial Mint commercialization ramp. This isn't just a hit to the share price; it's a direct threat to their core product roadmap. We peel the news before it peels you. Source & full breakdown: Wiseek (link in bio)